March 21, 2014 / 2:50 PM / 3 years ago

U.S. lawmakers ask Gilead about Sovaldi pricing

March 21 (Reuters) - U.S. lawmakers have asked for a briefing from Gilead Sciences Inc on the price of new hepatitis C drug Sovaldi.

A letter to Gilead from Democrats in the House Energy & Commerce Committee asks for information on Sovaldi discounts to payors and patients.

The recently approved medicine, seen as a breakthrough in the treatment of the serious liver disease, costs about $84,000 per patient.

Gilead shares were down 4 percent in morning trading on Nasdaq. (Reporting by Michele Gershberg and Bill Berkrot; Editing by Jeffrey Benkoe)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below